© 2004 by Society
© 2004 by the Society forNeuro-Oncology
Review of microdialysis in brain tumors, from concept to application:First Annual Carolyn Frye-Halloran Symposium
Brain Tumor Center, Massachusetts General Hospital,Boston, MA 02114 (R.K.B., F.H.H.); National CancerInstitute, Bethesda, MD 20892 (E.F.); NationalInstitutes of Health, Bethesda, MD 20892 (P.M.B); Department of Pharmaceutics, University of Minnesota,Minneapolis, MN 55455 (W.F.E.); St. Jude Children'sResearch Hospital, Memphis, TN 38105 (C.F.S.); Department of Pharmacology, Fox Chase Cancer Center,Philadelphia, PA 19111 (J.M.G.); Laboratory ofClinical Pharmacology, Center for Drug Evaluation and Research, Food and DrugAdministration, Rockville, MD 20857 (J.M.C.); CMAMicrodialysis, North Chelmsford, MA 01863 (R.P.P); TheUniversity of Texas M.D. Anderson Cancer Center, Houston, TX 77030(J.F.D.); Human Performance Laboratory, East CarolinaUniversity, Greenville, NC 27858 (R.C.H.); PsychiatryDepartment, Yale University, New Haven, CT 06519 (I.C.); Department of Neuro-Oncology, Sidney Kimmel ComprehensiveCancer Center at Johns Hopkins, Baltimore, MD 21231 (S.A.G.); Department of Medicine, Duke University Medical Center,Durham, NC 27710 (O.M.C.); USA
1 Address correspondence to Ramsis K. Benjamin, Carolina Neurosurgery &Spine Associates, Neuro-Oncology Center, 1628 E. Morehead Road, Suite 200,Charlotte, NC 28207(Ramsis.benjamin{at}cnsa.com).
 |
Abstract |
|---|
In individuals with brain tumors, pharmacodynamic and pharmacokineticstudies of therapeutic agents have historically used analyses of drugconcentrations in serum or cerebrospinal fluid, which unfortunately do notnecessarily reflect concentrations within the tumor and adjacent brain. Thisreview article introduces to neurological and medical oncologists, as well aspharmacologists, the application of microdialysis in monitoring drugmetabolism and delivery within the fluid of the interstitial space of braintumor and its surroundings. Microdialysis samples soluble molecules from theextracellular fluid via a semipermeable membrane at the tip of a probe. In thepast decade, it has been used predominantly in neurointensive care in thesetting of brain trauma, vasospasm, epilepsy, and intracerebral hemorrhage. Atthe first Carolyn Frye-Halloran Symposium held at Massachusetts GeneralHospital in March 2002, the concept of microdialysis was extended tospecifically address its possible use in treating brain tumor patients. Indoing so we provide a rationale for the use of this technology by a NationalCancer Institute consortium, New Approaches to Brain Tumor Therapy, to measurelevels of drugs in brain tissue as part of phase 1 trials.
Received March 25, 2003; Accepted September 22, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Portnow, B. Badie, M. Chen, A. Liu, S. Blanchard, and T. W. Synold The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation Clin. Cancer Res., November 15, 2009; 15(22): 7092 - 7098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, R. F. Barth, G. Wu, M. J. Ciesielski, R. A. Fenstermaker, B. A. Moffat, B. D. Ross, and C. J. Wikstrand Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Targeting Studies with Monoclonal Antibody L8A4 Clin. Cancer Res., January 1, 2005; 11(1): 341 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Barth, W. Yang, A. S. Al-Madhoun, J. Johnsamuel, Y. Byun, S. Chandra, D. R. Smith, W. Tjarks, and S. Eriksson Boron-Containing Nucleosides as Potential Delivery Agents for Neutron Capture Therapy of Brain Tumors Cancer Res., September 1, 2004; 64(17): 6287 - 6295. [Abstract] [Full Text] [PDF]
|
|